Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by retiredcopon May 22, 2021 10:09am
175 Views
Post# 33253750

RE:Who is steering the ship right now?

RE:Who is steering the ship right now?I agree that the timing was a bit off on this pr and its only normal to try and comprehend why someone could be so incompotent....but given that I have always followed a basic principle... things that make no sense happen for a very specific reason and I started to think .. why was this done at this time...... the one reason that came to mind ... " word has gotten out that the FDA is going to make a call on Biogen early next week"   this could explain a reason to announce that  they are developing the cell line for PMN310. How about very soon, PMN preparing to make a formal  announcenement  of the intent to conduct clinical trials .  Timing this info in anticipation of a positive FDA ruling on Biogen , could be very advantageous to PMN . Even the negative outcome for Biogen, would allow PMN to say Biogen was not approved and we think we have something that addresses the FDA concern. I just like to look at all angles of an issue , because sometimes  we get tunnel vision and just focus on what appears obvious.  
<< Previous
Bullboard Posts
Next >>